Company news

Imugene Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Further Responses in azer-cel Phase 1b Trial

October 18, 2026

Further Responses in azer-cel Phase 1b Trial

October 18, 2026

azer-cel BTKi Cohort Reports new Complete & Partial Response

October 4, 2026

Third response in concurrent BTKi Cohort of azer-cel Trial

July 26, 2026

$11.1 Million Placement Completed to Advance azer-cel

July 6, 2026

New Complete Response in the Concurrent BTKi azer-cel Cohort

June 30, 2026

First Complete Response in Concurrent BTKi azer-cel Cohort

June 29, 2026

Azer-cel Granted FDA Fast Track Designation for CLL and MZL

June 8, 2026

First Patient in BTKi Combination Cohort of azer-cel study

May 27, 2026

Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract

May 21, 2026

Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)

May 20, 2026

Prospectus

March 17, 2026

$20M placement and SPP, convertible notes amended

March 11, 2026

100% and 80% ORRs in Subset Indications in azer-cel study

March 9, 2026

Trading Halt

March 9, 2026

Half Yearly Report and Accounts

February 25, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

FDA Supports Strategy Toward Registration for Azer-cel

December 7, 2025

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

November 27, 2025

Strategic Collaboration with JW Therapeutics

November 26, 2025

S&P DJI Announces September 2025 Quarterly Rebalance

September 5, 2025

Final Share Purchase Plan Allotment

August 28, 2025

Appendix 4E and Annual Report

August 25, 2025

Imugene Capital Raising Presentation

July 16, 2025

Imugene Completes $22.5M Placement and c.$15M SPP

July 16, 2025

Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL

July 14, 2025

Two Additional Complete Responses in azer-cel Ph1b trial

July 13, 2025

Notice of Extraordinary General Meeting/Proxy Form

May 27, 2025

Azer-cel Granted FDA Fast Track Designation in Blood Cancer

March 18, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Imugene Granted India Patent for Oncolytic Virotherapy CF33

February 26, 2025

Imugene OnCARlytics Patent Allowance in China

February 25, 2025

Azer-cel demonstrates two additional Complete Responses

February 13, 2025

Imugene Receives A$20 million for Convertible Notes Issuance

January 28, 2025

Imugene Receives $11.7m R&D Tax Refund

January 10, 2025

First Australian Patient Dosed in Phase 1b azer-cel Trial

January 2, 2025

Issuance of Convertible Notes & Warrants for up to $46m

December 23, 2024

Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund

December 18, 2024

onCARlytics Trial Doses First Patient in IT Combination Arm

November 10, 2024

Imugene Opens First Australian Site for azer-cel Trial

November 7, 2024

Complete Response in MAST Study Maintained Over Two Years

November 4, 2024

Imugene Receives Orphan Drug Designation for VAXINIA

September 18, 2024

Three Complete Responses in Azer-Cel Phase 1b Trial

September 1, 2024

First patient dosed in Phase 1 bile tract cancer trial

July 9, 2024

Imugene onCARlytics Doses First Patient in IV Combination

June 23, 2024

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

April 16, 2024

Imugene and Kincell Bio Announce Strategic Partnership

April 15, 2024

Bile Tract Cancer Study Opens after MAST High Dose Clearance

April 14, 2024

Older news releases →

Decks

The 5 newest of 46 decks. Every deck is listed under its year.